Researchers in the Nanoscience Center at the University of Jyväskylä, Finland, have developed a pioneering computational ...

A generalizable ML framework predicts protein interactions with ligand-stabilized gold nanoclusters, supporting faster design ...

Iambic, a clinical-stage life sciences and technology company advancing novel medicines through its AI-driven discovery and development platform, today announced that Tom Miller, Ph.D. (Co-Founder and ...

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Can the weakened immune systems of older individuals be rejuvenated? Researchers from the German Cancer Research Center (DKFZ ...

AI drug discovery company Syntekabio (CEO Jung Jongseon) announced on November 24 that its research on the large language model (LLM)-based ...

PRISM BioLab, Co. Ltd. ('PRISM') and Talus Bioscience, Inc. ('Talus Bio') announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and ...

At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that ...

In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

The novel drug atacicept was associated with significant reductions in proteinuria vs. placebo with comparable safety and no ...